ArticleCell reports. Medicine2025
Optimal post-treatment surveillance strategy for human papillomavirus-positive oropharyngeal cancer.
Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The objective of the current study was to determine the optimal individualized surveillance strategies for human papillomavirus (HPV)-positive oropharyngeal cancer. A consecutive cohort of 1,146 HPV-positive oropharyngeal cancer patients treated by intensity-modulated radiation therapy between 2013 and 2023 was included. The primary endpoint was the power of detecting recurrence at each follow-up. Three distinct, stage-specific follow-up strategies were developed based on the monthly probability of disease recurrence. Over a 5-year post-treatment period, the total number of follow-up visits was 10, 11, and 12 for Stages I, II, and III, respectively. These risk-adapted follow-up strategies demonstrated superior detection efficiency when compared to existing clinical guidelines. Furthermore, validation using Markov decision-analytic models confirmed that the risk-based strategies were both more effective and cost-efficient than the guideline-recommended strategy. Compared to the surveillance strategies recommended by the clinical guidelines, our proposed approach for HPV-positive oropharyngeal cancer demonstrated greater cost-effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.